Organization and Liquidity - Additional information (Details) $ / shares in Units, $ in Thousands		9 Months Ended
	Sep. 19, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) Program	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 20, 2023 shares
Organization and Liquidity [Line items]
Number of clinical and preclinical neuroscience programs | Program		7
Reverse stock split		7.8463-for-1
Reverse stock split conversion ratio			0.1274
Proceeds from initial public offering			$ 232,565
Preferred stock, shares authorized | shares					50,000,000
Accumulated deficit		$ (888,402)		$ (703,434)
Cash and cash equivalents		275,714	$ 412,284	374,038
Marketable securities		65,593		$ 79,944
Initial Public Offering
Organization and Liquidity [Line items]
Common stock sold in initial public offering | shares	14,710,000
Price to public, per share | $ / shares	$ 17
Proceeds from initial public offering	$ 226,500
Underwriting discounts and commissions	17,500
Offering expenses	$ 6,000
Common stock shares authorized | shares	700,000,000
Common stock, par value | $ / shares	$ 0.0001
Preferred stock, shares authorized | shares	50,000,000
Preferred stock, par value | $ / shares	$ 0.0001
Number of convertible preferred stock automatically converted into shares of common stock | shares	104,417,415
Liquidity
Organization and Liquidity [Line items]
Accumulated deficit		888,400
Cash, cash equivalents, and marketable securities		$ 341,300